Ocuphire Pharma Price to Sales Ratio 2010-2024 | IRD
Historical PS ratio values for Ocuphire Pharma (IRD) over the last 10 years. The current P/S ratio for Ocuphire Pharma as of October 24, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Ocuphire Pharma P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-10-24 |
1.13 |
|
1.56 |
| 2024-06-30 |
1.53 |
$0.72 |
2.11 |
| 2024-03-31 |
2.01 |
$0.86 |
2.35 |
| 2023-12-31 |
3.01 |
$0.87 |
3.46 |
| 2023-09-30 |
3.35 |
$0.79 |
4.23 |
| 2023-06-30 |
4.34 |
$0.26 |
16.77 |
| 2023-03-31 |
3.75 |
$0.08 |
44.90 |
| 2022-12-31 |
3.53 |
0 |
0.00 |
| 2022-09-30 |
2.01 |
0 |
0.00 |
| 2022-06-30 |
1.92 |
$0.03 |
66.45 |
| 2022-03-31 |
3.24 |
$0.04 |
89.40 |
| 2021-12-31 |
3.73 |
$0.04 |
102.92 |
| 2021-09-30 |
5.15 |
$0.04 |
142.11 |
| 2021-06-30 |
5.28 |
$0.01 |
0.00 |
| 2021-03-31 |
5.81 |
0 |
0.00 |
| 2020-12-31 |
6.49 |
0 |
0.00 |
| 2020-09-30 |
8.32 |
0 |
0.00 |
| 2020-06-30 |
11.36 |
0 |
0.00 |
| 2020-03-31 |
7.20 |
0 |
0.00 |
| 2019-12-31 |
7.64 |
0 |
0.00 |
| 2019-09-30 |
8.20 |
0 |
0.00 |
| 2019-06-30 |
20.64 |
0 |
0.00 |
| 2019-03-31 |
24.48 |
0 |
0.00 |
| 2018-12-31 |
44.64 |
0 |
0.00 |
| 2018-09-30 |
85.44 |
0 |
0.00 |
| 2018-06-30 |
67.68 |
0 |
0.00 |
| 2018-03-31 |
72.48 |
0 |
0.00 |
| 2017-12-31 |
96.96 |
0 |
0.00 |
| 2017-09-30 |
116.16 |
0 |
0.00 |
| 2017-06-30 |
137.28 |
0 |
0.00 |
| 2017-03-31 |
244.80 |
0 |
0.00 |
| 2016-12-31 |
68.11 |
0 |
0.00 |
| 2016-09-30 |
100.80 |
0 |
0.00 |
| 2016-06-30 |
120.58 |
0 |
0.00 |
| 2016-03-31 |
158.45 |
0 |
0.00 |
| 2015-12-31 |
174.24 |
0 |
0.00 |
| 2015-09-30 |
249.60 |
0 |
0.00 |
| 2015-06-30 |
291.70 |
0 |
0.00 |
| 2015-03-31 |
350.40 |
0 |
0.00 |
| 2014-12-31 |
336.00 |
0 |
0.00 |
| 2014-09-30 |
388.80 |
0 |
0.00 |
| 2014-06-30 |
417.60 |
0 |
0.00 |
| 2014-03-31 |
518.40 |
0 |
0.00 |
| 2013-12-31 |
244.80 |
0 |
0.00 |
| 2013-09-30 |
218.35 |
0 |
0.00 |
| 2013-06-30 |
213.12 |
0 |
0.00 |
| 2013-03-31 |
146.40 |
0 |
0.00 |
| 2012-12-31 |
148.80 |
0 |
0.00 |
| 2012-09-30 |
242.40 |
0 |
0.00 |
| 2012-06-30 |
153.60 |
0 |
0.00 |
| 2012-03-31 |
254.40 |
0 |
0.00 |
| 2011-12-31 |
180.48 |
0 |
0.00 |
| 2011-09-30 |
480.00 |
0 |
0.00 |
| 2011-06-30 |
595.20 |
0 |
0.00 |
| 2011-03-31 |
566.40 |
$0.12 |
4657.74 |
| 2010-12-31 |
537.60 |
$0.25 |
2180.75 |
| 2010-09-30 |
556.80 |
$0.25 |
2258.63 |
| 2010-06-30 |
686.40 |
$0.39 |
1740.21 |
| 2010-03-31 |
777.60 |
$0.43 |
1817.05 |
| 2009-12-31 |
326.40 |
$0.47 |
698.81 |
| Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
|
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|
